{"name":"argenx SE","slug":"argenx","ticker":"ARGX","exchange":"NASDAQ","domain":"argenx.com","description":"argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A","hq":"Breda, Netherlands","founded":0,"employees":"1863","ceo":"Tim Van Hauwermeiren","sector":"Biotech","stockPrice":779.44,"stockChange":14.01,"stockChangePercent":1.83,"marketCap":"$48.7B","metrics":{"revenue":4236468992,"revenueGrowth":73,"grossMargin":57.2,"rdSpend":0,"netIncome":1292034944,"cash":4440038912,"dividendYield":0,"peRatio":39.7,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Vyvgart","genericName":"EFGARTIGIMOD ALFA","slug":"efgartigimod-alfa","revenue":2500000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"2021-01-01","label":"Vyvgart first approved","drug":"Vyvgart","drugSlug":"efgartigimod-alfa","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"Efgartigimod patent cliff ($1.4B at risk)","drug":"Efgartigimod","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":2500000000,"percentOfTotal":100,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Vyvgart","genericName":"EFGARTIGIMOD ALFA","slug":"efgartigimod-alfa","indication":"Immune thrombocytopenia","status":"marketed","revenue":2500000000},{"name":"ARGX-113","genericName":"ARGX-113","slug":"argx-113","indication":"Generalized myasthenia gravis (gMG)","status":"phase_3"},{"name":"ARGX-113 with rHuPH20","genericName":"ARGX-113 with rHuPH20","slug":"argx-113-with-rhuph20","indication":"Primary immunodeficiency","status":"phase_1"},{"name":"Empasiprubart IV","genericName":"Empasiprubart IV","slug":"empasiprubart-iv","indication":"Generalized myasthenia gravis (gMG)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":8,"colorKey":"cardiovascular","drugs":[{"name":"efgartigimod IV","genericName":"efgartigimod IV","slug":"efgartigimod-iv","indication":"Generalized myasthenia gravis","status":"phase_3"},{"name":"ARGX-109","genericName":"ARGX-109","slug":"argx-109","indication":"Other","status":"phase_1"},{"name":"ARGX-111","genericName":"ARGX-111","slug":"argx-111","indication":"Other","status":"phase_1"},{"name":"ARGX-117","genericName":"ARGX-117","slug":"argx-117","indication":"Treatment of generalized myasthenia gravis","status":"phase_2"},{"name":"ARGX-117 PH20 SC","genericName":"ARGX-117 PH20 SC","slug":"argx-117-ph20-sc","indication":"Other","status":"phase_1"},{"name":"ARGX-119 IV","genericName":"ARGX-119 IV","slug":"argx-119-iv","indication":"Treatment of generalized myasthenia gravis","status":"phase_2"},{"name":"ARGX-124","genericName":"ARGX-124","slug":"argx-124","indication":"Other","status":"phase_1"},{"name":"Efgartigimod IV or Efgartigimod PH20 SC","genericName":"Efgartigimod IV or Efgartigimod PH20 SC","slug":"efgartigimod-iv-or-efgartigimod-ph20-sc","indication":"Myasthenia Gravis","status":"phase_2"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"EFG PH20 SC","genericName":"EFG PH20 SC","slug":"efg-ph20-sc","indication":"Relapsing forms of multiple sclerosis","status":"phase_2"},{"name":"ARGX-213","genericName":"ARGX-213","slug":"argx-213","indication":"Chronic inflammatory demyelinating polyneuropathy (CIDP)","status":"phase_1"},{"name":"Efgartigimod PH20 SC","genericName":"Efgartigimod PH20 SC","slug":"efgartigimod-ph20-sc","indication":"Generalized myasthenia gravis (gMG)","status":"marketed"}]}],"pipeline":[{"name":"Vyvgart","genericName":"EFGARTIGIMOD ALFA","slug":"efgartigimod-alfa","phase":"marketed","mechanism":"Vyvgart works by binding to the p51 subunit of the FcRn receptor, preventing it from recycling antibodies back into the bloodstream.","indications":["Immune thrombocytopenia","Myasthenia gravis"],"catalyst":""},{"name":"EFG PH20 SC","genericName":"EFG PH20 SC","slug":"efg-ph20-sc","phase":"phase_2","mechanism":"EFG PH20 SC is a monoclonal antibody targeting ephrin type-A receptor 4 (EphA4).","indications":["Relapsing forms of multiple sclerosis"],"catalyst":""},{"name":"efgartigimod IV","genericName":"efgartigimod IV","slug":"efgartigimod-iv","phase":"phase_3","mechanism":"Efgartigimod IV is a monoclonal antibody that targets and depletes neonatal Fc receptor (FcRn), thereby reducing the levels of immunoglobulin G (IgG) in the body.","indications":["Generalized myasthenia gravis"],"catalyst":""},{"name":"ARGX-109","genericName":"ARGX-109","slug":"argx-109","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ARGX-111","genericName":"ARGX-111","slug":"argx-111","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ARGX-113","genericName":"ARGX-113","slug":"argx-113","phase":"phase_3","mechanism":"ARGX-113 is a monoclonal antibody that blocks the neonatal Fc receptor (FcRn) to reduce circulating immunoglobulin levels, particularly IgG antibodies.","indications":["Generalized myasthenia gravis (gMG)","IgG-mediated autoimmune conditions"],"catalyst":""},{"name":"ARGX-113 with rHuPH20","genericName":"ARGX-113 with rHuPH20","slug":"argx-113-with-rhuph20","phase":"phase_1","mechanism":"Monoclonal antibody targeting the neonatal Fc receptor (FcRn)","indications":["Primary immunodeficiency"],"catalyst":""},{"name":"ARGX-117","genericName":"ARGX-117","slug":"argx-117","phase":"phase_2","mechanism":"ARGX-117 is a monoclonal antibody targeting CD70.","indications":["Treatment of generalized myasthenia gravis"],"catalyst":""},{"name":"ARGX-117 PH20 SC","genericName":"ARGX-117 PH20 SC","slug":"argx-117-ph20-sc","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ARGX-119 IV","genericName":"ARGX-119 IV","slug":"argx-119-iv","phase":"phase_2","mechanism":"ARGX-119 IV is a monoclonal antibody targeting CD70.","indications":["Treatment of generalized myasthenia gravis"],"catalyst":""},{"name":"ARGX-124","genericName":"ARGX-124","slug":"argx-124","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ARGX-213","genericName":"ARGX-213","slug":"argx-213","phase":"phase_1","mechanism":"Monoclonal antibody targeting CD20","indications":["Chronic inflammatory demyelinating polyneuropathy (CIDP)"],"catalyst":""},{"name":"Efgartigimod IV or Efgartigimod PH20 SC","genericName":"Efgartigimod IV or Efgartigimod PH20 SC","slug":"efgartigimod-iv-or-efgartigimod-ph20-sc","phase":"phase_2","mechanism":"Monoclonal antibody targeting muscle relaxant proteins","indications":["Myasthenia Gravis"],"catalyst":""},{"name":"Efgartigimod PH20 SC","genericName":"Efgartigimod PH20 SC","slug":"efgartigimod-ph20-sc","phase":"marketed","mechanism":"Efgartigimod is an IgG Fc fragment that binds to the neonatal Fc receptor (FcRn) to reduce circulating immunoglobulin levels, particularly IgG antibodies.","indications":["Generalized myasthenia gravis (gMG)","Chronic inflammatory demyelinating polyneuropathy (CIDP)"],"catalyst":""},{"name":"Empasiprubart IV","genericName":"Empasiprubart IV","slug":"empasiprubart-iv","phase":"phase_3","mechanism":"Empasiprubart is a FcRn (neonatal Fc receptor) antagonist that reduces the recycling and extends the half-life of IgG antibodies, enhancing their therapeutic activity.","indications":["Generalized myasthenia gravis (gMG)","Other autoimmune conditions (under investigation)"],"catalyst":""}],"recentEvents":[{"date":"2023-02-16","type":"regulatory","headline":"argenx Announces FDA Approval of Efgartigimod for Generalized Myasthenia Gravis","summary":"argenx announced that the FDA has approved efgartigimod for the treatment of generalized myasthenia gravis.","drugName":"Efgartigimod","sentiment":"positive"},{"date":"2022-02-24","type":"earnings","headline":"argenx Reports Fourth Quarter and Full Year 2021 Financial Results","summary":"argenx reported its financial results for the fourth quarter and full year 2021, with revenue of $1.4 billion.","drugName":"","sentiment":"neutral"},{"date":"2021-06-15","type":"deal","headline":"argenx Announces Collaboration with AbbVie to Develop and Commercialize Efgartigimod","summary":"argenx announced a collaboration with AbbVie to develop and commercialize efgartigimod in the United States.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNSUFzLXBlZlFrM0lFVEo3SkpENmdkVnNmY3g1U0xLdF9uTUE2RVRLQk9RT2hSN1FobWNqbkxYSkVKU0dIdVVDZGlkbW44TVktb2RBYTJrNnA4UTJKT05jS2x1ZUdvaExNV0h3b2ZyVC1YWE1ZWlZOQ2toaVZpcFhoaS1RWmtONXdWaUotUy1kZS1FbmVpd0ZwU1gtcm1qcFlFSTRkR0RETzZYVHFUcVdoZ0dkRmM0VllTNUtWS3VZbmY?oc=5","date":"2026-04-02","type":"deal","source":"The Globe and Mail","summary":"Argenx Se (ARGX) Gets a Buy from Wells Fargo - The Globe and Mail","headline":"Argenx Se (ARGX) Gets a Buy from Wells Fargo","sentiment":"neutral"},{"date":"2026-03-20","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-19","type":"earnings","source":"SEC EDGAR","summary":"20-F filed with SEC: 20-F","headline":"Annual Report (20-F) Filed","sentiment":"neutral"},{"date":"2026-03-19","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxONkZPS1djTDI3OTcxZ2E2SElxME1vVlZzeUNVelpJUGV1T21IbmxZZHU2UWdEREpZSi1RNklsS2RrWEZRX2lsZnhTQ1RoSjhYSVVDUEd3a09iNW1BYW9HenF4QkpteW1JYWZ6OGRZN2JieHdrLU1mTG44TndyVk1uWDhsa015eW9jZmVBNFozV05WY3J1cXZLeE9rMWg5b0JhYXd1STE2QWRoR0RJTU5GcGxublJvRzZxWEhCaXZmWmk2SkZ4dTA1RHVIV2RGSTFEcjZwLVZCM2wzbm1nWGV0MGlxblJOeENRRnVUUkdGM2lPYk1IWmZFVFhMdmVqZ04xajl1d2QwSmNKTlpnN0E?oc=5","date":"2026-03-18","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: NeurAxis, Inc. (NRXS), Argenx Se (ARGX) and Teladoc (TDOC) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: NeurAxis, Inc. (NRXS), Argenx Se (ARGX) and Teladoc (TDOC)","sentiment":"neutral"},{"date":"2026-03-06","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQcmxuNFRWUXk5eUR6M2RlU3JEYzdiMGZ1czFjaFhKZTFfVWRzVWJneHh0ZWdaa08taDhiaWNQTDRzYXRQOUxHSzh1cU9DbFp4eEFDaloyakcyeDg5aEZmMVJvRGMxbDFzRndRSEFsUW1uWHhrbTJVd2pfMUh3ekxNRmZsSl9mMTFNS3RXOU5ETGI2WkpKa1M2ZmdBZU93YW0yLWJzd0J2VWgtZVU3SDQ0LU9rcUrSAbwBQVVfeXFMUFFjNXpZam5LNEpGWjR0SzF6RTg1ZjVnbDVhaklLVWpvSXJwdDlaWWJ0UkxaMWFBZXFSZnplQWYxSTV5UWtGUXY5bk9Xa0twSzg1bXhXOUVQd1QyVmZLUzBzUHFoR3c5YklkQTFjZW1odUhmcWx0ZmJUQ2JQZWVqMGR0VFZFQ2t2UkZsY3hzalJ3ckdscDlQR3lZNVdmUmI3OTB3dHk0cllhTDNSamFrOU1ZaHlYa2dyVUpnNjM?oc=5","date":"2026-02-03","type":"earnings","source":"Insider Monkey","summary":"Analysts May Have Underestimated Argenx SE’s (ARGX) 5 year Revenue Growth - Insider Monkey","headline":"Analysts May Have Underestimated Argenx SE’s (ARGX) 5 year Revenue Growth","sentiment":"neutral"},{"date":"2026-01-13","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQdVJ4a3hPSVBDWjhCQldKTGtOeGdwSzVvdk1aajNzZ1kxajBnRUFOYno0V3h2ZnhJUUhVU25DTXBVOU5OUW5TNGhPcWE5NjZIdHhfaDJTTllTOS1wUXVidGNuR3QwTU5oMFlOT1dfSVVlM0EtVXFUR2JrQlgzcTVLUktDY0JSUUpQd1g0Ml8zSnItUGdaaE85SHFZa3BiRm8zZ3lSaWNTb2syNGl0Vjcyc3ZRSkZJQQ?oc=5","date":"2026-01-12","type":"pipeline","source":"GlobeNewswire","summary":"argenx Highlights 2026 Strategic Priorities - GlobeNewswire","headline":"argenx Highlights 2026 Strategic Priorities","sentiment":"neutral"},{"date":"2026-01-12","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-01-05","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2025-12-15","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2025-11-18","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"}],"patents":[{"drugName":"Efgartigimod","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":1400000000}],"drugCount":15,"phaseCounts":{"marketed":2,"phase_2":4,"phase_3":3,"phase_1":6},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["BioNTech","Regeneron","Sanofi"],"therapeuticFocus":["Autoimmune Diseases","Neurological Disorders"],"financials":{"source":"sec_edgar","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":null,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":null,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":779.44,"previousClose":765.43,"fiftyTwoWeekHigh":934.62,"fiftyTwoWeekLow":510.06,"fiftyTwoWeekRange":"510.055 - 934.62","fiftyDayAverage":772.97,"twoHundredDayAverage":756.87,"beta":-0.09,"enterpriseValue":43111915520,"forwardPE":23.4,"priceToBook":6.59,"priceToSales":11.5,"enterpriseToRevenue":10.18,"enterpriseToEbitda":40.6,"pegRatio":1.19,"ebitda":1061902016,"ebitdaMargin":25.1,"freeCashflow":512832992,"operatingCashflow":685192000,"totalDebt":47160000,"debtToEquity":0.6,"currentRatio":5.23,"returnOnAssets":8.9,"returnOnEquity":20.2,"analystRating":"1.5 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":22,"targetMeanPrice":1031.3,"targetHighPrice":1256.04,"targetLowPrice":700.98,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0,"institutionHeldPercent":49,"sharesOutstanding":62187771,"floatShares":61977241,"sharesShort":1889528,"shortRatio":5.13,"shortPercentOfFloat":3,"epsTrailing":19.61,"epsForward":33.26,"revenuePerShare":2.76,"bookValue":118.34,"officers":[{"age":53,"name":"Mr. Timothy  Van Hauwermeiren EMBA, M.Sc.","title":"Co-Founder, CEO & Executive Director"},{"age":55,"name":"Mr. Karl  Gubitz","title":"Chief Financial Officer"},{"age":46,"name":"Ms. Karen  Massey","title":"Chief Operating Officer"},{"age":45,"name":"Dr. Peter  Ulrichts","title":"Chief Scientific Officer"},{"age":55,"name":"Ms. Malini  Moorthy","title":"General Counsel & Corporate Secretary"},{"age":40,"name":"Mr. Arjen  Lemmen M.Sc.","title":"Vice President of Corporate Development & Strategy"},{"age":51,"name":"Ms. Andria  Wilk","title":"Global Head of Quality"},{"age":60,"name":"Dr. Luc  Truyen","title":"Chief Medical Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://argenx.com","phone":"31 10 703 8441"}}